ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Erasca, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$13.62+0.23 (+1.72%)
Close on Oct 19, 2026
- Market cap
- $4.24B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.4%
281M of 350M shares
Institutional holders
257
63 new, 27 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $2.28M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jonathan E. Lim | 36,968,486 | 10.40% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick J. Heron | 22,575,851 | 8.00% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Investment Management, Inc. | 21,224,264 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| Venrock Healthcare Capital Partners EG, L.P. | 16,382,812 | 5.30% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong | 16,157,175 | 5.20% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 15,358,280 | 5.40% | 13G (passive) | Sep 30, 2024 |
| Arsani William | 15,100,000 | 5.30% | 13G (passive) | Jun 30, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 15,038,753 | 5.30% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ERAS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | 7.14% | $457.55M | +300,000 | 9.96% |
| T. Rowe Price Investment Management, Inc. | 21,185,839 | 6.06% | $388.13K | −73,807 | 0.25% |
| BlackRock, Inc. | 21,154,146 | 6.05% | $387.54M | +1,002,740 | 0.01% |
| Rtw Investments, LP | 17,946,754 | 5.13% | $328.78M | +1,789,579 | 2.81% |
| VR Adviser, LLC | 17,891,812 | 5.12% | $327.78M | +1,509,000 | 9.94% |
| State Street Corp | 12,184,555 | 3.48% | $223.22M | +2,884,471 | 0.01% |
| Logos Global Management LP | 12,150,000 | 3.47% | $222.59M | +1,000,000 | 9.58% |
| Vanguard Capital Management LLC | 11,402,199 | 3.26% | $208.89M | +152,461 | 0.00% |
| Siren, L.L.C. | 11,397,781 | 3.26% | $208.81M | +153,535 | 4.23% |
| Paradigm Biocapital Advisors LP | 9,550,000 | 2.73% | $174.96M | −842,702 | 3.28% |
| ARCH Venture Management, LLC | 7,091,557 | 2.03% | $129.92M | – | 11.81% |
| Geode Capital Management, LLC | 6,501,426 | 1.86% | $119.13M | +505,277 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 6,272,508 | 1.79% | $114.91K | +4,457,168 | 0.01% |
| Cormorant Asset Management, LP | 6,000,000 | 1.72% | $109.92M | +200,000 | 5.63% |
| Affinity Asset Advisors, LLC | 5,250,000 | 1.50% | $96.18M | −100,000 | 4.35% |
| Vivo Capital, LLC | 4,127,412 | 1.18% | $75.61M | −8,024,068 | 6.90% |
| Alliancebernstein L.P. | 4,118,614 | 1.18% | $66.64M | +1,473,694 | 0.02% |
| Goldman Sachs Group Inc | 3,822,113 | 1.09% | $70.02M | −1,053,073 | 0.01% |
| Bank Of America Corp /De/ | 3,048,737 | 0.87% | $55.85M | −7,160 | 0.00% |
| FMR LLC | 2,883,417 | 0.82% | $52.82M | +1,393,337 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 257 | 281M | 80.4% | 63 / 102 | 77 / 27 | 46M | 35M |
| Q1 2026 | 225 | 274M | 78.3% | 97 / 77 | 39 / 23 | 100M | 38M |
| Q4 2025 | 154 | 224M | 64.1% | 32 / 45 | 46 / 18 | 18M | 10M |
| Q3 2025 | 141 | 216M | 61.8% | 17 / 41 | 43 / 16 | 9M | 11M |
| Q2 2025 | 142 | 219M | 62.5% | 25 / 59 | 38 / 36 | 16M | 22M |
| Q1 2025 | 154 | 224M | 64.1% | 28 / 49 | 47 / 18 | 9M | 15M |
| Q4 2024 | 146 | 231M | 66.0% | 27 / 52 | 39 / 12 | 15M | 18M |
| Q3 2024 | 132 | 234M | 66.9% | 26 / 53 | 30 / 18 | 61M | 28M |
| Q2 2024 | 126 | 212M | 60.5% | 39 / 51 | 24 / 20 | 151M | 14M |
| Q1 2024 | 108 | 74M | 21.2% | 20 / 30 | 44 / 31 | 13M | 9M |
| Q4 2023 | 119 | 70M | 20.0% | 28 / 42 | 34 / 14 | 16M | 15M |
| Q3 2023 | 109 | 71M | 20.4% | 9 / 49 | 29 / 12 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ERAS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8,384,454 | 2.40% | $153.60M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,447,165 | 2.13% | $136.43M | 1.27% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 6,954,600 | 1.99% | $127.41M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,137,080 | 1.47% | $94.11M | 0.11% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3,334,921 | 0.95% | $61.10M | 0.66% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,746,433 | 0.79% | $50.31M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 2,584,513 | 0.74% | $47.35M | 0.40% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 2,533,680 | 0.72% | $32.53M | 0.62% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,409,217 | 0.69% | $43.73M | 0.13% | Jul 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,786,568 | 0.51% | $32.73M | 0.65% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,667,210 | 0.48% | $30.54M | 0.20% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 1,523,521 | 0.44% | $27.91M | 0.18% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,435,300 | 0.41% | $26.29M | 0.27% | Jun 30, 2026 |
| Victory Pioneer Select Mid Cap Growth Fund | 1,332,535 | 0.38% | $17.11M | 0.90% | May 31, 2026 |
| iShares Biotechnology ETF | 1,325,097 | 0.38% | $24.28M | 0.27% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan E. Lim | Chairman & CEO, Director, 10% owner | 32,355,576 | 9.25% | Jan 30, 2026 |
| Charles S. Fuchs | President, R&D | – | – | Aug 12, 2026 |
| Ebun Garner | Chief Legal Officer | 105,076 | 0.03% | Apr 3, 2026 |
| Shannon Morris | Chief Medical Officer | 20,000 | 0.01% | Mar 6, 2026 |
| David M. Chacko | CFO and CBO | 279,980 | 0.08% | Jan 30, 2026 |
| Pratik S. Multani | Director | 172,866 | 0.05% | Jun 29, 2026 |
| Julie Hambleton | Director | 6,000 | 0.00% | Jun 29, 2026 |
| Valerie Denise Harding Start | Director | 22,000 | 0.01% | Jun 29, 2026 |
| Alexander W. Casdin | Director | 667,724 | 0.19% | Jun 29, 2026 |
| James Arthur Bristol | Director | 207,500 | 0.06% | Jun 29, 2026 |
| Jean I. Liu | Director | – | – | Jun 29, 2026 |
| Michael David Varney | Director | – | – | Jan 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ebun Garner Chief Legal Officer | Apr 1, 2026 | Option exercise | +80,000 | $1.70 | $136.00K | 105,076 |
| Ebun Garner Chief Legal Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −80,000 | $16.40 | $1.31M | 25,076 |
| Shannon Morris Chief Medical Officer | Mar 4, 2026 | Option exercise | +20,000 | $1.70 | $34.00K | 20,000 |
| Shannon Morris Chief Medical Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −20,000 | $15.04 | $300.80K | 0 |
| Ebun Garner General Counsel & Corp. Sec. | Jan 7, 2026 | Option exercise | +120,000 | $1.70 | $204.00K | 145,076 |
| Ebun Garner General Counsel & Corp. Sec. | Jan 7, 2026 | Sale(10b5-1 plan) | −120,000 | $5.59 | $670.80K | 25,076 |
| David M. Chacko CFO and CBO | Dec 15, 2025 | Other | +17,793 | $1.19 | $21.17K | 279,980 |
| Ebun Garner General Counsel & Corp. Sec. | Dec 15, 2025 | Award | +3,902 | $1.19 | $4.64K | 25,076 |
| Pratik S. Multani Director | May 23, 2025 | Gift | −6,200 | – | – | 166,666 |
| Pratik S. Multani Director | May 23, 2025 | Gift | +6,200 | – | – | 6,200 |
| David M. Chacko CFO and CBO | Dec 13, 2024 | Other | +12,324 | $1.56 | $19.23K | 262,187 |
| Ebun Garner General Counsel & Corp. Sec. | Dec 13, 2024 | Other | +5,731 | $1.56 | $8.94K | 21,174 |
| David M. Chacko CFO and CBO | Jun 14, 2024 | Other | +3,137 | $1.56 | $4.89K | 262,187 |
| Ebun Garner General Counsel & Corp. Sec. | Jun 14, 2024 | Other | +5,715 | $1.56 | $8.92K | 21,174 |
| Alexander W. Casdin Director | May 21, 2024 | Buy | +80,000 | $2.27 | $181.60K | 573,974 |
| David M. Chacko CFO and CBO | Dec 15, 2023 | Other | +7,478 | $1.59 | $11.89K | 246,726 |
| Ebun Garner General Counsel & Corp. Sec. | Dec 15, 2023 | Other | +5,448 | $1.59 | $8.66K | 9,728 |
| Valerie Denise Harding Start Director | Dec 6, 2023 | Buy | +10,000 | $1.85 | $18.50K | 20,000 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Dec 6, 2023 | Buy | +278,150 | $1.72 | $478.42K | 12,899,360 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Dec 5, 2023 | Buy | +721,850 | $1.69 | $1.22M | 12,899,360 |
| Alexander W. Casdin Director | Dec 4, 2023 | Buy | +30,000 | $1.66 | $49.80K | 493,974 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Oct 5, 2023 | Buy | +1,000,000 | $2.03 | $2.03M | 19,456,216 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Jun 8, 2023 | Buy | +100,000 | $2.75 | $275.00K | 18,396,216 |
| Alexander W. Casdin Director | Apr 10, 2023 | Buy | +20,000 | $2.76 | $55.20K | 463,974 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Mar 28, 2023 | Buy | +100,000 | $2.84 | $284.00K | 18,296,216 |
| Ebun Garner General Counsel & Corp. Sec. | Feb 1, 2023 | Other | +2,388 | $4.10 | $9.79K | 4,280 |
| Ebun Garner General Counsel & Corp. Sec. | Feb 1, 2023 | Other | +2 | $3.89 | $8 | 4,280 |
| Lin Wei Chief Medical Officer | Feb 1, 2023 | Other | +1,748 | $4.10 | $7.17K | 315,812 |
| Lin Wei Chief Medical Officer | Feb 1, 2023 | Other | +2 | $3.89 | $8 | 315,812 |
| David M. Chacko Chief Financial Officer | Feb 1, 2023 | Other | +2 | $3.89 | $8 | 239,248 |
| David M. Chacko Chief Financial Officer | Feb 1, 2023 | Other | +1,748 | $4.10 | $7.17K | 239,248 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Jan 10, 2023 | Buy | +60,000 | $3.86 | $231.60K | 20,256,222 |
| Valerie Denise Harding Start Director | Dec 21, 2022 | Buy | +10,000 | $4.64 | $46.40K | 10,000 |
| James Arthur Bristol Director | Dec 21, 2022 | Buy | +20,000 | $4.14 | $82.80K | 20,000 |
| Alexander W. Casdin Director | Dec 15, 2022 | Buy | +20,000 | $4.87 | $97.40K | 443,974 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Dec 14, 2022 | Buy | +40,000 | $4.99 | $199.60K | 20,196,222 |
| Cormorant Asset Management, LP Director | Dec 13, 2022 | Buy | +307,692 | $6.50 | $2.00M | 10,813,246 |
| Cormorant Asset Management, LP Director | Dec 13, 2022 | Buy | +307,692 | $6.50 | $2.00M | 10,813,246 |
| Jonathan E. Lim Chairman and CEO, Director, 10% owner | Nov 30, 2022 | Gift | −2,000,006 | – | – | 18,196,216 |
| Alexander W. Casdin Director | Jul 1, 2022 | Other | −750,000 | – | – | 0 |
| Lin Wei Chief Medical Officer | Feb 1, 2022 | Other | +1,562 | $11.60 | $18.12K | 314,062 |
| David M. Chacko Chief Financial Officer | Feb 1, 2022 | Other | +1,562 | $11.60 | $18.12K | 237,498 |
| Ebun Garner General Counsel & Corp. Sec. | Feb 1, 2022 | Other | +990 | $11.60 | $11.48K | 1,890 |
| Bihua Chen Director | Aug 10, 2021 | Buy | +200,000 | $22.10 | $4.42M | 10,505,553 |
| Bihua Chen Director | Jul 26, 2021 | Sale | −200,000 | $18.77 | $3.75M | 10,305,553 |
| Cormorant Asset Management, LP 10% owner | Jul 20, 2021 | Buy | +950,000 | $16.00 | $15.20M | 10,505,553 |
| Cormorant Asset Management, LP 10% owner | Jul 20, 2021 | Conversion | +9,555,553 | – | – | 9,555,553 |
| Alexander W. Casdin Director | Jul 20, 2021 | Conversion | +150,000 | – | – | 337,500 |
| Alexander W. Casdin Director | Jul 20, 2021 | Conversion | +750,000 | – | – | 750,000 |
| Kristina Burow 10% owner | Jul 20, 2021 | Conversion | +5,527,777 | – | – | 5,527,777 |
| Kristina Burow 10% owner | Jul 20, 2021 | Conversion | +5,527,777 | – | – | 5,527,777 |
| Valerie Denise Harding Start Director | Jul 20, 2021 | Buy | +2,000 | $16.00 | $32.00K | 2,000 |
| Pratik S. Multani Director | Jul 20, 2021 | Buy | +6,200 | $16.00 | $99.20K | 172,866 |
| Julie Hambleton Director | Jul 20, 2021 | Buy | +6,000 | $16.00 | $96.00K | 6,000 |
| City Hill, LLC 10% owner | Jul 20, 2021 | Conversion | +5,135,390 | – | – | 20,156,222 |
| City Hill, LLC 10% owner | Jul 20, 2021 | Conversion | +5,441,027 | – | – | 11,899,360 |
| Ebun Garner General Counsel | Jul 20, 2021 | Buy | +900 | $16.00 | $14.40K | 900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Foundation Erasca Foundation | Oct 15, 2026 | 8,333 | $122.35K | Oct 15, 2026 | Donation |
| Foundation Erasca Foundation | Sep 15, 2026 | 8,333 | $133.09K | Sep 15, 2026 | Donation |
| Foundation Erasca Foundation | Aug 17, 2026 | 8,333 | $152.42K | Aug 17, 2026 | Donation |
| Foundation Erasca Foundation | Jul 21, 2026 | 8,333 | $157.64K | Jul 21, 2026 | Donation |
| Foundation Erasca Foundation | Jun 15, 2026 | 8,333 | $117.48K | Jun 15, 2026 | Donation |
| Foundation Erasca Foundation | May 15, 2026 | 8,333 | $84.53K | May 15, 2026 | Donation |
| Foundation Erasca Foundation | Apr 15, 2026 | 8,333 | $150.84K | Apr 15, 2026 | Donation |
| Foundation Erasca Foundation | Apr 15, 2026 | 8,333 | $150.84K | Apr 15, 2026 | Donation |
| Garner Ebun Officer | Apr 1, 2026 | 80,000 | $1.31M | Apr 1, 2026 | Stock Option |
| Foundation Erasca Foundation | Mar 16, 2026 | 8,333 | $116.86K | Mar 16, 2026 | Donation |
| Morris Shannon Officer | Mar 4, 2026 | 20,000 | $300.77K | Mar 4, 2026 | Stock Option |
| Foundation Erasca Foundation | Feb 17, 2026 | 8,333 | $99.25K | Feb 17, 2026 | Donation |
| Foundation Erasca Foundation | Jan 15, 2026 | 8,333 | $68.57K | Jan 15, 2026 | Donation |
| Garner Ebun Officer | Jan 7, 2026 | 120,000 | $670.81K | Jan 7, 2026 | Stock Option |
| Foundation Erasca Foundation | Dec 15, 2025 | 8,333 | $30.44K | Dec 15, 2025 | Donation |